Cerretti G, Bosio A, Librizzi G, Pintacuda G, Caccese M, Salvalaggio A
J Neurooncol. 2025; .
PMID: 40063186
DOI: 10.1007/s11060-025-04992-4.
Chen K, Jiang B, Yan H, Yang L, Chen Z
Front Oncol. 2025; 15:1395129.
PMID: 39995836
PMC: 11847825.
DOI: 10.3389/fonc.2025.1395129.
Luo J, Yi T, Wang Y, Song W, Gao Z, Wang J
Sci Rep. 2025; 15(1):4902.
PMID: 39929852
PMC: 11811180.
DOI: 10.1038/s41598-024-82400-z.
Lin S, Tang R, Ye Y, Xia C, Wu J, Duan R
Molecules. 2025; 30(2).
PMID: 39860127
PMC: 11767819.
DOI: 10.3390/molecules30020257.
Atkinson G, Ben-Ami Y, Maini P, Pitt-Francis J, Byrne H
Bull Math Biol. 2025; 87(2):30.
PMID: 39847152
PMC: 11757897.
DOI: 10.1007/s11538-024-01404-y.
Assessing cross-country inequalities in global burden of gastrointestinal cancers: slope and concentration index approach.
Zhou H, Wang Y, Wang F, Meng R, Yu Y, Han S
Discov Oncol. 2025; 16(1):41.
PMID: 39806164
PMC: 11729605.
DOI: 10.1007/s12672-025-01762-6.
Radiation-Induced Brain Injury: Mechanistic Insights and the Promise of Gut-Brain Axis Therapies.
Li M, Tong F, Wu B, Dong X
Brain Sci. 2025; 14(12.
PMID: 39766494
PMC: 11674909.
DOI: 10.3390/brainsci14121295.
Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors.
Zhou Y, Liu Z, Yu A, Zhao G, Chen B
Immunotargets Ther. 2025; 13:813-829.
PMID: 39763508
PMC: 11700879.
DOI: 10.2147/ITT.S494670.
Association of genetically proxied cancer-targeted drugs with cardiovascular diseases through Mendelian randomization analysis.
Fang C, Liu X, Yu C, Li S, Liu X, Qiu S
J Transl Med. 2025; 23(1):14.
PMID: 39762845
PMC: 11702226.
DOI: 10.1186/s12967-024-06027-4.
Exploring the Interaction of Biotinylated FcGamma RI and IgG1 Monoclonal Antibodies on Streptavidin-Coated Plasmonic Sensor Chips for Label-Free VEGF Detection.
Khaligh S, Khalid-Salako F, Kurt H, Yuce M
Biosensors (Basel). 2024; 14(12).
PMID: 39727899
PMC: 11674972.
DOI: 10.3390/bios14120634.
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.
Wu S, Ho C, Yang J, Yu S, Lin Y, Lin S
Clin Transl Med. 2024; 15(1):e70149.
PMID: 39715697
PMC: 11666332.
DOI: 10.1002/ctm2.70149.
Oxygen, angiogenesis, cancer and immune interplay in breast tumour microenvironment: a computational investigation.
Mirzaei N, Kevrekidis P, Shahriyari L
R Soc Open Sci. 2024; 11(12):240718.
PMID: 39665095
PMC: 11631512.
DOI: 10.1098/rsos.240718.
Pulmonary vascular manifestations of hereditary haemorrhagic telangiectasia.
Cullivan S, Kevane B, McCullagh B, OConnor T, Condliffe R, Gaine S
Pulm Circ. 2024; 14(4):e70007.
PMID: 39588537
PMC: 11586239.
DOI: 10.1002/pul2.70007.
Comparison of Efficacy, Safety, and Economic Outcomes Between Biosimilar ABP 215 and Originator Bevacizumab in Japanese Patients With Colorectal Cancer.
Sumimoto T, Tanaka R, Tatsuta R, Kubota M, Itoh H
Cureus. 2024; 16(10):e72260.
PMID: 39583480
PMC: 11584936.
DOI: 10.7759/cureus.72260.
Vascular Endothelial Growth Factor and the Pathogenesis of Intracranial Aneurysms: A Systematic Review on the Missing Link in a Complex Pathway.
Nisson P, Lawton M, Cisneros O, Maeda T, Gonzalez N, Frosen J
J Am Heart Assoc. 2024; 13(23):e035638.
PMID: 39575766
PMC: 11681557.
DOI: 10.1161/JAHA.124.035638.
Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer.
Deng X, Liu J
Transl Breast Cancer Res. 2024; 5:32.
PMID: 39534580
PMC: 11557168.
DOI: 10.21037/tbcr-24-21.
Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study.
Zheng Z, Zhao Y, Xie J, Gao M, Wang Y, Li X
Front Pharmacol. 2024; 15:1463026.
PMID: 39525635
PMC: 11543948.
DOI: 10.3389/fphar.2024.1463026.
Efficacy and safety of different angiogenesis inhibitors combined with PARP inhibitors in the treatment of ovarian cancer: A systematic review and meta‑analysis.
Huang X, Luo J, Gu L
Oncol Lett. 2024; 29(1):36.
PMID: 39512502
PMC: 11542167.
DOI: 10.3892/ol.2024.14782.
Engineering growth factor ligands and receptors for therapeutic innovation.
An X, Paoloni J, Oh Y, Spangler J
Trends Cancer. 2024; 10(12):1131-1146.
PMID: 39389907
PMC: 11631651.
DOI: 10.1016/j.trecan.2024.09.006.
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.
Li Q, Geng S, Luo H, Wang W, Mo Y, Luo Q
Signal Transduct Target Ther. 2024; 9(1):266.
PMID: 39370455
PMC: 11456611.
DOI: 10.1038/s41392-024-01953-7.
